Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 1, 2025, reports a material definitive agreement entered into by Citius Pharmaceuticals, Inc. The Company, incorporated in Nevada and trading on the Nasdaq Capital Market, announced a registered direct offering that closed on April 2, 2025.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 465,000 shares of common stock and pre-funded warrants to purchase up to 1,274,131 shares.
- Offering Prices: $1.15 per share for common stock; $1.1499 per pre-funded warrant.
- Net Proceeds: Approximately $1.735 million after deducting placement agent fees and offering expenses.
- Placement Agent Fees: H.C. Wainwright and Co., LLC received a cash fee of 7.0% of gross proceeds, plus reimbursement for legal fees (up to $25,000), non-accountable expenses ($10,000), and a clearing fee ($10,000).
- Placement Agent Warrants: The Company granted warrants to purchase up to 121,739 shares at an exercise price of $1.4375 per share.
Material Changes and Transaction Terms
The filing details the terms of the securities purchase agreement, including a 30-day lock-up period during which the Company cannot issue additional securities convertible into common stock, subject to exceptions. Pre-funded warrants are immediately exercisable at $0.0001 per share and are subject to a beneficial ownership limitation of 4.99% (or 9.99% at the holder's election). Placement agent warrants are exercisable six months after issuance and expire five years from the commencement of sales.
Outlook, Management Commentary, and Use of Proceeds
Management intends to use the net proceeds to support the commercial launch of the Company's product, LYMPHIR™, and for general corporate purposes. The offering was conducted pursuant to an effective registration statement on Form S-3 previously declared effective by the SEC on March 1, 2024.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the status of the commercial launch timeline for LYMPHIR™.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the exercise of pre-funded warrants and placement agent warrants for potential future dilution.
- Check subsequent filings for updates on the utilization of the $1.735 million in net proceeds.